A review of onabotulinumtoxinA (Botox).

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M Sykes, Heidi A. Waldorf

Research output: Contribution to journal › Article

10 Citations (Scopus)

Abstract

OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.

Original languageEnglish (US)
JournalAesthetic surgery journal / the American Society for Aesthetic Plastic surgery
Volume33
Issue number1 Suppl
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Type A Botulinum Toxins
Esthetics
Safety
onabotulinumtoxinA
Handling (Psychology)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lorenc, Z. P., Kenkel, J. M., Fagien, S., Hirmand, H., Nestor, M. S., Sclafani, A. P., ... Waldorf, H. A. (2013). A review of onabotulinumtoxinA (Botox). Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, 33(1 Suppl). https://doi.org/10.1177/1090820X12474629

A review of onabotulinumtoxinA (Botox). / Lorenc, Z. Paul; Kenkel, Jeffrey M.; Fagien, Steven; Hirmand, Haideh; Nestor, Mark S.; Sclafani, Anthony P.; Sykes, Jonathan M; Waldorf, Heidi A.

In: Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, Vol. 33, No. 1 Suppl, 03.2013.

Research output: Contribution to journal › Article

Lorenc, ZP, Kenkel, JM, Fagien, S, Hirmand, H, Nestor, MS, Sclafani, AP, Sykes, JM & Waldorf, HA 2013, 'A review of onabotulinumtoxinA (Botox).', Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery, vol. 33, no. 1 Suppl. https://doi.org/10.1177/1090820X12474629
Lorenc ZP, Kenkel JM, Fagien S, Hirmand H, Nestor MS, Sclafani AP et al. A review of onabotulinumtoxinA (Botox). Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery. 2013 Mar;33(1 Suppl). https://doi.org/10.1177/1090820X12474629
Lorenc, Z. Paul ; Kenkel, Jeffrey M. ; Fagien, Steven ; Hirmand, Haideh ; Nestor, Mark S. ; Sclafani, Anthony P. ; Sykes, Jonathan M ; Waldorf, Heidi A. / A review of onabotulinumtoxinA (Botox). In: Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery. 2013 ; Vol. 33, No. 1 Suppl.
@article{a6eb03e4343b4e94bec993f51fc3f001,
title = "A review of onabotulinumtoxinA (Botox).",
abstract = "OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.",
author = "Lorenc, {Z. Paul} and Kenkel, {Jeffrey M.} and Steven Fagien and Haideh Hirmand and Nestor, {Mark S.} and Sclafani, {Anthony P.} and Sykes, {Jonathan M} and Waldorf, {Heidi A.}",
year = "2013",
month = "3",
doi = "10.1177/1090820X12474629",
language = "English (US)",
volume = "33",
journal = "Aesthetic Surgery Journal",
issn = "1090-820X",
publisher = "SAGE Publications Inc.",
number = "1 Suppl",

}

TY - JOUR

T1 - A review of onabotulinumtoxinA (Botox).

AU - Lorenc, Z. Paul

AU - Kenkel, Jeffrey M.

AU - Fagien, Steven

AU - Hirmand, Haideh

AU - Nestor, Mark S.

AU - Sclafani, Anthony P.

AU - Sykes, Jonathan M

AU - Waldorf, Heidi A.

PY - 2013/3

Y1 - 2013/3

N2 - OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.

AB - OnabotulinumtoxinA was introduced to the US market in 2002 as the first botulinum toxin type A (BoNTA) approved for facial aesthetics. This article provides an overview of onabotulinumtoxinA's uses and indications as well as safety and efficacy data. As with other BoNTA products, onabotulinumtoxinA is generally well tolerated. Consideration is also given to clinical applications of the product. Information on handling, storage, and dosing is provided.

UR - http://www.scopus.com/inward/record.url?scp=84882937423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882937423&partnerID=8YFLogxK

U2 - 10.1177/1090820X12474629

DO - 10.1177/1090820X12474629

M3 - Article

VL - 33

JO - Aesthetic Surgery Journal

JF - Aesthetic Surgery Journal

SN - 1090-820X

IS - 1 Suppl

ER -

Access to Document